113,028 Shares in Vir Biotechnology, Inc. $VIR Purchased by OP Asset Management Ltd

Posted by Brian Himes on Jun 30th, 2026

OP Asset Management Ltd bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) during the first quarter, HoldingsChannel.com reports. The fund bought 113,028 shares of the company’s stock, valued at approximately $1,013,000.

Other institutional investors have also recently bought and sold shares of the company. Diversified Trust Co boosted its position in Vir Biotechnology by 13.6% during the 1st quarter. Diversified Trust Co now owns 32,038 shares of the company’s stock worth $287,000 after acquiring an additional 3,836 shares during the last quarter. Rockefeller Capital Management L.P. raised its holdings in shares of Vir Biotechnology by 187.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 29,869 shares of the company’s stock valued at $180,000 after purchasing an additional 19,472 shares during the last quarter. Corient Private Wealth LLC raised its holdings in shares of Vir Biotechnology by 1.0% in the fourth quarter. Corient Private Wealth LLC now owns 262,211 shares of the company’s stock valued at $1,572,000 after purchasing an additional 2,515 shares during the last quarter. Virtus Investment Advisers LLC lifted its position in shares of Vir Biotechnology by 82.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 39,764 shares of the company’s stock worth $240,000 after purchasing an additional 17,966 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Vir Biotechnology in the fourth quarter worth $414,000. Institutional investors own 65.32% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Leerink Partners raised their target price on shares of Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a research report on Wednesday, June 3rd. HC Wainwright boosted their price target on shares of Vir Biotechnology from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Friday, April 10th. Wall Street Zen downgraded shares of Vir Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Morgan Stanley raised their price objective on Vir Biotechnology from $23.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Vir Biotechnology has a consensus rating of “Moderate Buy” and a consensus price target of $20.88.

View Our Latest Report on VIR

Vir Biotechnology Stock Performance

Shares of VIR stock opened at $10.38 on Tuesday. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $11.66. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -3.32 and a beta of 1.65. The firm’s 50-day moving average is $9.45 and its 200-day moving average is $8.39.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.84). The business had revenue of ($0.03) million for the quarter, compared to the consensus estimate of $55.49 million. Vir Biotechnology had a negative return on equity of 53.31% and a negative net margin of 638.88%.During the same quarter in the previous year, the business posted ($0.88) EPS. Sell-side analysts predict that Vir Biotechnology, Inc. will post -1.81 EPS for the current fiscal year.

Insider Transactions at Vir Biotechnology

In related news, Director Vicki L. Sato sold 22,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $9.07, for a total transaction of $199,540.00. Following the transaction, the director directly owned 1,100,391 shares of the company’s stock, valued at approximately $9,980,546.37. The trade was a 1.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Backer Marianne De sold 72,559 shares of the stock in a transaction on Monday, April 6th. The shares were sold at an average price of $9.16, for a total value of $664,640.44. Following the completion of the sale, the chief executive officer owned 948,145 shares in the company, valued at approximately $8,685,008.20. This trade represents a 7.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 120,138 shares of company stock worth $1,119,102. 2.90% of the stock is owned by company insiders.

Vir Biotechnology Company Profile

(Free Report)

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.